People
As countries reopen businesses and move toward normalcy, emerging biotech companies in the U.S. and Europe have encountered a mixed bag of experiences.
As of June 29, there were 13 vaccines against COVID-19 in human clinical trials.
In a forthcoming paper, 239 scientists from more than 30 countries are pushing the World Health Organization to pay more attention to the possible airborne spread of SARS-CoV-2.
Biopharma and life sciences companies bolster their executive teams and board with these Movers & Shakers.
By using the herpes simplex virus (HSV) as a helper for its adeno-associated viral (AAV) platform, Applied Genetic Technologies Corporation (AGTC) created AAVs that are more robust, purer and lower cost than any of the other methods.
Moderna has always been an odd and secretive company. Currently all eyes are on the company because it is the furthest along in developing a vaccine against COVID-19.
The “printers” are portable, automated messenger RNA (mRNA) production units, which Elon Musk referred to as “RNA microfactories.”
Meet with regulatory affairs professionals early and often. That’s the message from Neelu Gibson, VP, regulatory affairs, at BD, speaking at Biocom’s June virtual meeting, “Regulatory Affairs…Engagement Do’s & Don’ts.”
Interferons are proteins produced by the body to fight viral infections by inhibiting its replication in the body.
Gilead Sciences set the price of the only approved treatment for COVID-19, remdesivir, at $390 per vial, which for most patients receiving a 5-day treatment using six vials, would come to $2,340 per patient.
PRESS RELEASES